1 results match your criteria: "Switzerland. IOSI Oncology Institute of Southern Switzerland[Affiliation]"
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Clin Cancer Res
April 2015
Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland. IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Purpose: In cancer cells, the epigenome is often deregulated, and inhibition of the bromodomain and extra-terminal (BET) family of bromodomain-containing proteins is a novel epigenetic therapeutic approach. Preliminary results of an ongoing phase I trial have reported promising activity and tolerability with the new BET bromodomain inhibitor OTX015.
Experimental Design: We assessed the preclinical activity of OTX015 as single agent and in combination in mature B-cell lymphoma models and performed in vitro and in vivo experiments to identify the mechanism of action and the genetic features associated with sensitivity to the compound.